Name	Nimodipine
Description	Nimodipine (BAY-e 9736), a 1, 4-dihydropyridine calcium channel blocker, acts primarily on vascular smooth muscle cells.
In vivo	Nimodipine (5-20 mg/kg, SC) suppresses in a dose-related manner self-administration both of cocaine and morphine contingent upon a nose-poke response. Nimodipine (10 mg/kg, SC), an L-type dihydropyridine Ca2+ channel antagonist, exhibits to completely block the establishment of conditioning of cocaine's effects, but only partially blocks sensitization to cocaine.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	Ethanol : 4.2 mg/mL (10 mM) DMSO : 60 mg/mL (143.39 mM)
Keywords	Nimodipine \| cerebrovascular \| dihydropyridine \| light-sensitive \| Ca2+ channels \| calcium \| well-tolerated \| Inhibitor \| Calcium Channel \| Autophagy \| orally \| inhibit \| Ca channels
Inhibitors Related	Stavudine \| Sodium 4-phenylbutyrate \| L-Ascorbic acid \| Hydroxychloroquine \| Guanidine hydrochloride \| Taurine \| Curcumin \| Paeonol \| Naringin \| Gefitinib
Related Compound Libraries	Bioactive Compound Library \| Anti-Cancer Clinical Compound Library \| Drug Repurposing Compound Library \| Neuroprotective Compound Library \| Inhibitor Library \| Anti-Cancer Approved Drug Library \| FDA-Approved Drug Library \| Anti-Aging Compound Library \| Ion Channel Targeted Library \| Anti-Cancer Drug Library

Nimodipine NEW

Product Introduction